Pocenbrodib (previously FT-7051) is a small molecule inhibitor that has the potential to provide clinical benefit for patients with advanced prostate cancer, either alone or in combination with other treatments.

Pocenbrodib (previously FT-7051) works by inhibiting CREBBP/EP300 (also known as CBP/P300), which are proteins that activate genes that promote cancer cell growth and proliferation. Inhibiting these proteins impacts the expression of key cancer drivers, including the androgen receptor (AR) and its variants, making pocenbrodib relevant not only to advanced prostate cancer but to a number of other cancer indications as well either alone or in combination with other treatments.